Teacher Retirement System of Texas Decreases Stock Position in Vericel Co. (NASDAQ:VCEL)

Teacher Retirement System of Texas lessened its stake in shares of Vericel Co. (NASDAQ:VCELFree Report) by 18.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 10,464 shares of the biotechnology company’s stock after selling 2,359 shares during the period. Teacher Retirement System of Texas’ holdings in Vericel were worth $373,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. DekaBank Deutsche Girozentrale purchased a new stake in Vericel in the fourth quarter worth $33,000. GAMMA Investing LLC purchased a new stake in Vericel in the fourth quarter worth $65,000. Sentry Investment Management LLC purchased a new stake in Vericel in the fourth quarter worth $136,000. PNC Financial Services Group Inc. increased its stake in Vericel by 8.1% in the third quarter. PNC Financial Services Group Inc. now owns 4,582 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 344 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Vericel in the fourth quarter worth $197,000.

Vericel Price Performance

Shares of VCEL stock opened at $48.23 on Tuesday. Vericel Co. has a 1-year low of $30.18 and a 1-year high of $53.05. The stock’s 50-day moving average is $48.36 and its 200 day moving average is $42.95. The company has a market cap of $2.34 billion, a P/E ratio of -4,823.00 and a beta of 1.74.

Vericel (NASDAQ:VCELGet Free Report) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The company had revenue of $51.28 million for the quarter, compared to the consensus estimate of $49.07 million. During the same quarter last year, the company earned ($0.16) earnings per share. The firm’s revenue for the quarter was up 25.0% compared to the same quarter last year. On average, analysts anticipate that Vericel Co. will post 0.1 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on VCEL. StockNews.com lowered Vericel from a “hold” rating to a “sell” rating in a research note on Monday. TheStreet raised Vericel from a “d+” rating to a “c-” rating in a research report on Monday, January 29th. Truist Financial reissued a “buy” rating and set a $54.00 price target on shares of Vericel in a research report on Tuesday, March 26th. Finally, HC Wainwright increased their price target on Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, Vericel has an average rating of “Moderate Buy” and an average target price of $46.80.

View Our Latest Stock Report on Vericel

Insider Activity at Vericel

In related news, Director Robert L. Md Zerbe sold 3,278 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total transaction of $169,046.46. Following the sale, the director now owns 23,395 shares of the company’s stock, valued at $1,206,480.15. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Vericel news, Director Robert L. Md Zerbe sold 3,278 shares of the firm’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $51.57, for a total value of $169,046.46. Following the completion of the sale, the director now owns 23,395 shares of the company’s stock, valued at $1,206,480.15. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Sean C. Flynn sold 8,115 shares of the firm’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $45.33, for a total value of $367,852.95. Following the completion of the sale, the senior vice president now directly owns 167 shares of the company’s stock, valued at approximately $7,570.11. The disclosure for this sale can be found here. Insiders have sold a total of 54,267 shares of company stock valued at $2,450,996 over the last quarter. 5.20% of the stock is owned by corporate insiders.

About Vericel

(Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Further Reading

Institutional Ownership by Quarter for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.